Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose intermittent sunitinib versus lomustine in recurrent glioblastoma
NL-OMON50728Phase 2Active, not recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Sep 2018
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in glioblastoma (GBM) comparing High-dose intermittent sunitinib with Lomustine control (2 arms). Primary endpoint: Six-month progression-free survival. Started Sep 2018; status: active, not recruiting.
02
Drugs
sunitiniblomustine
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NL-OMON50728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50728.